MA51565A - Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble - Google Patents

Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble

Info

Publication number
MA51565A
MA51565A MA051565A MA51565A MA51565A MA 51565 A MA51565 A MA 51565A MA 051565 A MA051565 A MA 051565A MA 51565 A MA51565 A MA 51565A MA 51565 A MA51565 A MA 51565A
Authority
MA
Morocco
Prior art keywords
intermediaries
preparation
guanylate cyclase
new processes
soluble guanylate
Prior art date
Application number
MA051565A
Other languages
English (en)
Inventor
Ahmad Hashash
Vishnu Vardhan Reddy Karnati
William Kissel
Takashi Nakai
Wayne C Schairer
Debra Jane Wallace
Yuguang Wang
Song Xue
Fenger Zhou
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/fr
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MA51565A publication Critical patent/MA51565A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA051565A 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble MA51565A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (fr) 2018-02-22 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Publications (1)

Publication Number Publication Date
MA51565A true MA51565A (fr) 2020-11-18

Family

ID=65279655

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051565A MA51565A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
MA71753A MA71753A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71753A MA71753A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Country Status (17)

Country Link
US (5) US11274096B2 (fr)
EP (3) EP4249469A3 (fr)
JP (2) JP7357621B2 (fr)
KR (3) KR102739727B1 (fr)
CN (3) CN118221665A (fr)
AU (3) AU2019206560B2 (fr)
BR (1) BR112020013985A2 (fr)
CA (1) CA3087943A1 (fr)
CL (3) CL2020001814A1 (fr)
ES (1) ES2963447T3 (fr)
IL (3) IL319883A (fr)
JO (1) JOP20200165A1 (fr)
MA (2) MA51565A (fr)
MX (3) MX2020007364A (fr)
SG (1) SG11202006311SA (fr)
TW (2) TWI821237B (fr)
WO (1) WO2019140095A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481818B1 (fr) * 2016-07-07 2023-09-06 Cyclerion Therapeutics, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble
EP4249469A3 (fr) 2018-01-10 2023-12-27 Cyclerion Therapeutics, Inc. Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
WO2024131860A1 (fr) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 Forme cristalline d'un composé indazole substitué par du fluor et son utilisation
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026692B1 (ru) * 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
RS63108B1 (sr) * 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulatori
EP3094327A1 (fr) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires
CA2961531A1 (fr) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
BR112018011154B1 (pt) 2015-11-30 2023-09-26 Cyclerion Therapeutics, Inc Dispersões sólidas compreendendo um estimulador de sgc
WO2018009602A2 (fr) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble
EP3481818B1 (fr) 2016-07-07 2023-09-06 Cyclerion Therapeutics, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble
EP4249469A3 (fr) 2018-01-10 2023-12-27 Cyclerion Therapeutics, Inc. Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble

Also Published As

Publication number Publication date
MA71753A (fr) 2025-05-30
JP2023182647A (ja) 2023-12-26
ES2963447T3 (es) 2024-03-27
CN118221665A (zh) 2024-06-21
CN111902410A (zh) 2020-11-06
US11274096B2 (en) 2022-03-15
EP4249469A2 (fr) 2023-09-27
US20220024909A1 (en) 2022-01-27
MX2020007364A (es) 2020-11-18
TWI888947B (zh) 2025-07-01
US20230339928A1 (en) 2023-10-26
IL275748B1 (en) 2024-09-01
IL275748A (en) 2020-08-31
MX2023000045A (es) 2023-02-01
CN111902410B (zh) 2024-04-19
CL2022000907A1 (es) 2022-10-21
SG11202006311SA (en) 2020-07-29
EP3737679B1 (fr) 2023-09-06
KR20200106920A (ko) 2020-09-15
CL2022000904A1 (es) 2022-10-21
AU2023270260B2 (en) 2026-01-29
IL314714A (en) 2024-10-01
US11708361B2 (en) 2023-07-25
AU2023270260A1 (en) 2023-12-07
IL319883A (en) 2025-05-01
JP7357621B2 (ja) 2023-10-06
JOP20200165A1 (ar) 2022-10-30
EP4249469A3 (fr) 2023-12-27
AU2019206560A1 (en) 2020-07-30
US12030874B2 (en) 2024-07-09
CN118184645A (zh) 2024-06-14
US20210053962A1 (en) 2021-02-25
US12275724B2 (en) 2025-04-15
CL2020001814A1 (es) 2020-11-06
JP7744955B2 (ja) 2025-09-26
TWI821237B (zh) 2023-11-11
KR102739727B1 (ko) 2024-12-05
EP4570797A3 (fr) 2025-09-03
JP2021511299A (ja) 2021-05-06
WO2019140095A8 (fr) 2020-06-18
EP3737679A1 (fr) 2020-11-18
AU2025202281A1 (en) 2025-04-17
KR20250048609A (ko) 2025-04-09
TW201932450A (zh) 2019-08-16
BR112020013985A2 (pt) 2020-12-01
AU2019206560B2 (en) 2023-08-24
EP4570797A2 (fr) 2025-06-18
MX2023000044A (es) 2023-02-01
IL275748B2 (en) 2025-01-01
AU2025202281A9 (en) 2025-05-15
CA3087943A1 (fr) 2019-07-18
US20250361228A1 (en) 2025-11-27
TW202402741A (zh) 2024-01-16
EP3737679C0 (fr) 2023-09-06
KR20250002720A (ko) 2025-01-07
WO2019140095A1 (fr) 2019-07-18
US20240391911A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
MA46479A (fr) Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
EP3642217A4 (fr) Procédés et intermédiaires pour la préparation de dérivés de l'acide biliaire
EP3504196A4 (fr) Procédés de préparation d'olaparib
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
EP3749769A4 (fr) Procédés de production d'alcaloïdes de type morphinane et de dérivés
EP3458531A4 (fr) Compositions de revêtement et leurs procédés de préparation
EP3529232A4 (fr) Dérivés d'acide sulfamique et procédés pour leur préparation
MA51565A (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3635022A4 (fr) Procédés de préparation de monomères fluorés fonctionnalisés, monomères fluorés et compositions pour les préparer
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA49705A (fr) Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation
MA45154A (fr) Procédés de préparation d'oligomères
EP3645529A4 (fr) Procédé pour la préparation de lifitegrast et d'intermédiaires de celui-ci
EP3429754A4 (fr) Cartouches de préparation d'échantillons et leurs procédés d'utilisation
EP3720456A4 (fr) Procédés d'enrichissement améliorés pour la préparation de compositions d'acide tannique
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
EP3481200A4 (fr) Procédés de préparation de 4-alcoxy-3-(acyl ou alkyl)oxypicolinamides
EP3466280A4 (fr) Procédé de préparation d'aliments transformés et aliments transformés préparés au moyen de ce procédé
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
IL263994B (en) Novel processes for preparation of soluble guanylate cyclase stimulators
EP3803416A4 (fr) Compositions et procédés de détection d'une lésion cérébrale traumatique